MedTrace Logo

Clinical Performance of Two Different Restorative Materials in Restoring Class II Cavities of Primary Molars

NCT06000085 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2023-09-13

No results posted yet for this study

Summary

The aim of the present study is to assess Flowable Giomer Beautifil Flow Plus X (Shofu Dental Corporation, Japan) and Glass-hybrid-added HVGIC, Equia Forte (GC Corporation, Tokyo,

Japan) in class II cavities of primary molars regarding the following objectives:

The primary objective To evaluate and compare the clinical performance of Flowable Giomer Beautifil Flow Plus X (Shofu Dental Corporation, Japan) and Glass-hybrid-added HVGIC, Equia Forte (GC Corporation, Tokyo, Japan) in restoring class II cavities of primary molars after 3,6, and 12 months. The secondary objective To assess the effect of different independent variables on the treatment outcome of the experimental restorative materials.

Research question:

Is there a difference in the clinical performance between flowable giomers and highly viscous glass ionomer in restoring class II cavities of primary molars?

Null Hypothesis There is no difference in the clinical performance between Flowable Giomer Beautifil Flow Plus X (Shofu Dental Corporation, Japan) and Glass-hybrid-added HVGIC, Equia Forte (GC Corporation, Tokyo, Japan) after one year of follow up.

Conditions

  • Dental Caries Class II

Interventions

PROCEDURE

restoration of proximal cavities of primary molars with flowable giomer

removal of proximal caries of primary molars and restoration of the cavities prepared by beautifil flow plus x

PROCEDURE

restoration of proximal cavities of primary molars with highly viscous glass ionomer cement

removal of proximal caries of primary molars and restoration of the cavities prepared by equia forte

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Sarah Emad · faculty of dentistry ain shams university

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
8 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-30
Primary Completion
2024-06-30
Completion
2024-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06000085 on ClinicalTrials.gov